Optimal Management Approaches in Pulmonary Arterial Hypertension: Expert Strategies in Current and Emerging Treatments

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2020 to July 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Actelion

Description:
Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder characterized by vascular remodeling of the pulmonary arteries which carry blood from the heart to the lungs. For those with PAH, the muscles within the arterial walls tighten, which can cause thickening and/or scar tissue to develop, increasingly narrowing their diameter. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure. About half of people diagnosed with PAH will not live past five years. In 2019, the 6th World Symposium on Pulmonary Hypertension proposed an updated diagnostic definition of PAH and The American College of Chest Physicians (ACCP) also published new treatment guidelines. There continue to be significant challenges in identifying and diagnosing PAH because it requires a combination of information. Evaluation to detect the presence of PAH requires a comprehensive set of tests which typically include laboratory testing, echocardiography, pulmonary function testing, assessment of exercise capacity with six-minute walk distance, imaging, and right heart catheterization. There are a wide variety of treatment options to help manage PAH including nonspecific and targeted pharmacologic intervention. These include monotherapy and combination therapies that can include prostacyclin/prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.

Upon completion of this activity, participants will be able to:

  • Analyze the most recent guidelines for optimal management of pulmonary arterial hypertension (PAH)

  • Identify strategic measures to improve identification of clinical symptoms for the most accurate assessment and diagnosis of PAH

  • Examine the efficacy and safety of current treatment options for PAH and the potential impact of emerging treatment data on improving outcomes

  • Explore strategies to effectively manage side effects and optimize therapy for patients with PAH

  • Discuss personalized strategies for a multidisciplinary approach to care for PAH to assure a patient’s treatment goals, long-term assessment, and comorbidities in order to improve patient outcomes

     

Faculty: Murali Chakinala, MD, FCCP
Professor of Medicine
Washington University School of Medicine
Director, WUSM & BJH Pulmonary Hypertension Care Center

Disclosure:

Dr. Chakinala serves on an advisory board or has consulted for Actelion, WebMD, Express Scripts, Arena, Trio Health Analytics, Acceleron, Phase Bio, and Altavant. He has received grants or research support from Actelion, Bayer, Medtronic, NIH, Reata, Liquidia, Phase Bio, Complexa, United Therapeutics, and Altavant. He serves on the speaker’s bureau for Bayer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Actelion

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue